Anzeige
Mehr »
Login
Donnerstag, 02.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Paukenschlag in USA: Cannabis-Neuregulierung durch DEA sorgt für Kursexplosion!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
42 Leser
Artikel bewerten:
(0)

STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31

MONROVIA, Calif., July 28, 2014 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye has rescheduled the release of its second quarter results and conference call with investors to July 31, 2014 at 5:00 p.m. EDT from July 30, 2014. The Company rescheduled the release date and conference call to enable senior management attendance at the funeral services for Hideo Watanabe, President of STAAR Japan, who passed away of Sunday, July 27, 2014. Mr. Watanabe had been President of STAAR Japan since 2011.

"Hideo led our Japanese operations for the past three years and was a contributor to STAAR's growing success in Japan and China. Hideo led the efforts on the manufacturing transfer of IOLs from Japan and also the efforts to increase sales results on IOLs in Japan. The entire STAAR team and Board of Directors mourn his passing and express our deepest condolences to his wife and three sons," said Barry Caldwell, President & CEO of STAAR. "While we regret the inconvenience caused to our shareholders with the one day delay in our reporting results, I feel it was important for me to personally attend the funeral services for a friend of the Company, the ophthalmic industry and the employees of STAAR Surgical throughout the world."

STAAR will host its conference call and webcast on Thursday, July 31 at 5:00 p.m. Eastern / 2:00 p.m. Pacific to discuss these results and recent corporate developments. The dial-in number for the conference call is 866-515-2907 for domestic participants and 617-399-5121 for international participants, both using the passcode 24164533. The Company will also be using slides to illustrate its second quarter results and operational progress. The slides and live webcast with accompanying slides can be accessed from the investor relations section of the STAAR website at www.staar.com.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion for seven days. This replay can be accessed by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers, both using passcode 54025734. An archived video webcast will also be available at www.staar.com.

About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems there for. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." More than 450,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in Aliso Viejo, CA and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.

CONTACT:

Investors

Media


EVC Group

EVC Group


Doug Sherk, 415-652-9100

Nicole Kruse, 212-850-6025

SOURCE STAAR Surgical

Lithium vs. Palladium - Zwei Rohstoff-Chancen traden
In diesem kostenfreien PDF-Report zeigt Experte Carsten Stork interessante Hintergründe zu den beiden Rohstoffen inkl. . Zudem gibt er Ihnen konkrete Produkte zum Nachhandeln an die Hand, inkl. WKNs.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.